Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 10/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GHSR | Q92847 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4163795 | 0.88 | P2RY12 (0.42) | P2RY12ALDH1A1CYP3A4 | |
| SCHEMBL4015932 | 0.86 | P2RY12 (0.41) | P2RY12CYP3A4MEN1MAPTKMT2A | |
| SCHEMBL4185716 | 0.85 | P2RY12 (0.38) | P2RY12CYP3A4 | |
| SCHEMBL4172769 | 0.83 | P2RY12 (0.41) | P2RY12ALDH1A1CYP3A4MEN1KMT2A | |
| SCHEMBL3941725 | 0.81 | P2RY12 (0.39) | P2RY12HSD17B10 | |
| SCHEMBL4165233 | 0.81 | P2RY12 (0.35) | P2RY12ALDH1A1CYP3A4 | |
| SCHEMBL4782938 | 0.79 | P2RY12 (0.40) | P2RY12ALDH1A1CYP3A4RECQL | |
| SCHEMBL4183172 | 0.79 | P2RY12 (0.54) | P2RY12CYP3A4 | |
| SCHEMBL4168802 | 0.78 | P2RY12 (0.60) | P2RY12CYP3A4 | |
| SCHEMBL4741411 | 0.78 | P2RY12 (0.45) | P2RY12CYP3A4MAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018166-A1 | New Pyridine Analogues X 161 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | claimed |
| WO-2009011627-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| US-20090018166-A1 | New Pyridine Analogues X 161 | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018166-A1 | New Pyridine Analogues X 161 | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885ALDH1A1 1717/4885HSD17B10 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.